ALS TDI and Regenesance Partner on ALS Treatment

The ALS Therapy Development Institute is collaborating with Dutch company Regenesance. Together, they will look for drug candidates that modulate the complement pathway to suppress the deleterious immune responses involved in neuronal cell death. Regenesance will screen for potential drugs and then ALSTDI will test promising candidates in ALS animal models.

Click here to read more.

Share this:
Facebooktwittergoogle_plusmailFacebooktwittergoogle_plusmail